386 related articles for article (PubMed ID: 27669031)
1. Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab: A Case Report.
Hofer S; Philipsenburg C; Weigand MA; Brenner T
A A Case Rep; 2016 Dec; 7(11):227-231. PubMed ID: 27669031
[TBL] [Abstract][Full Text] [Related]
2. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
Tireli D; He J; Nordling MM; Wienecke T
J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
[TBL] [Abstract][Full Text] [Related]
3. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
Sheikh-Taha M
Am J Health Syst Pharm; 2019 Jan; 76(1):9-12. PubMed ID: 31381100
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
5. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
Giustozzi M; Verso M; Agnelli G; Becattini C
J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
[TBL] [Abstract][Full Text] [Related]
6. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
[TBL] [Abstract][Full Text] [Related]
7. Reversal of Dabigatran with Idarucizumab.
Sodha NR; Sellke FW
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
[TBL] [Abstract][Full Text] [Related]
8. Reversal of dabigatran by idarucizumab: when and how?
Vanassche T; Greinacher A; Verhamme P
Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
[TBL] [Abstract][Full Text] [Related]
9. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
Miyares MA; Kuyumjian Y; Eaves S; Dollard E
J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
[TBL] [Abstract][Full Text] [Related]
10. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
Syed YY
Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
[TBL] [Abstract][Full Text] [Related]
12. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Rosenberg L; Gerstrøm G; Nybo M
Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
[TBL] [Abstract][Full Text] [Related]
13. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
[TBL] [Abstract][Full Text] [Related]
14. Idarucizumab: First Global Approval.
Burness CB
Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
[TBL] [Abstract][Full Text] [Related]
15. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
Thibault N; Morrill AM; Willett KC
Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
[TBL] [Abstract][Full Text] [Related]
16. Idarucizumab for dabigatran overdose.
Peetermans M; Pollack C; Reilly P; Liesenborghs L; Jacquemin M; Levy JH; Weitz JI; Verhamme P
Clin Toxicol (Phila); 2016 Sep; 54(8):644-6. PubMed ID: 27224445
[TBL] [Abstract][Full Text] [Related]
17. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.
Brennan Y; Favaloro EJ; Pasalic L; Keenan H; Curnow J
Intern Med J; 2019 Jan; 49(1):59-65. PubMed ID: 29869387
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
Pollack CV; Bernstein R; Dubiel R; Reilly P; Gruenenfelder F; Huisman MV; Kam CW; Kleine E; Levy JH; Sellke FW; Steiner T; Ustyugova A; Weitz JI
J Med Econ; 2017 May; 20(5):435-442. PubMed ID: 27981865
[TBL] [Abstract][Full Text] [Related]
19. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
[TBL] [Abstract][Full Text] [Related]
20. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
Bissig D; Manjunath R; Traylor BR; Richman DP; Ng KL
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):e102-e104. PubMed ID: 28416406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
